Olivér Éliás

Title: Olivér Éliás: Innovator in GABAA A5 Receptor Modulation

Introduction

Olivér Éliás is a notable inventor based in Marcali, Hungary. He has made significant contributions to the field of pharmacology, particularly in the development of compounds that target the GABAA A5 receptor. His innovative work has the potential to impact the treatment of various neurological disorders.

Latest Patents

Olivér Éliás holds a patent for "Bicyclic derivatives as GABAA A5 receptor modulators." This invention provides compounds that exhibit affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5. These compounds act as GABAα5 negative allosteric modulators, making them useful in the treatment or prevention of diseases related to the GABAα5 receptor. The patent also covers the process for preparing these compounds, pharmaceutical compositions that include them, and their use as medicaments.

Career Highlights

Olivér Éliás is associated with Richter Gedeon Nyrt., a prominent pharmaceutical company. His work there has focused on the development of innovative therapeutic solutions that address critical health issues. With a patent portfolio that includes 1 patent, he has established himself as a key figure in his field.

Collaborations

Throughout his career, Olivér has collaborated with esteemed colleagues such as György Szabó and György István Túrós. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical compounds.

Conclusion

Olivér Éliás is a distinguished inventor whose work in GABAA A5 receptor modulation holds promise for advancing medical treatments. His contributions to the field of pharmacology are noteworthy and reflect his commitment to innovation.